The global next generation diabetes therapy and drug delivery market was valued at $7,080.6 million in 2020 and is projected to reach $28,044.23 million by 2030, registering a CAGR of 14.28% from 2021 to 2030. The next generation diabetes therapy and the drug delivery devices are the advanced form of diabetic products that improve the quality of life of diabetic patients. These products help in the management of the blood glucose level of diabetic patient in minimally invasive manner. Oral and inhalable insulin introduce a different mode of insulin delivery in diabetic patients. It is a painless mode of introducing insulin than the injectable insulins, reducing the risk of skin irritation caused due to needles. In addition, the dose volume is easily calculated in oral & inhalable insulin and helps to maintain the dosage time. Advanced diabetic therapy in the form of insulin patches, continuous glucose monitoring systems (CGMS), and artificial pancreas helps to improve management of blood sugar level and reduces the risk of any diabetic-related complications.
The main factors that drive the growth of the next generation diabetes therapy and the drug delivery market include, the benefits of using these advanced devices over conventional products and rise in the healthcare expenditure.
In addition, rise in incidences of diabetes globally and increase in the disposable income among the diabetic patients, further supplement the global next generation diabetes therapy and drug delivery market growth.
Conversely lack of awareness, cost restrains in the developing regions, and less variability in products are expected to obstruct the growth of the market during forecast years. On the other hand, development of affordable products with fewer side effects and presence of undiagnosed diabetic patients globally are expected to offer profitable opportunities for the growth of the market during the forecast period.
The global next generation diabetes therapy and drug delivery market is segmented based on product, demographic, indication, end user, and region. On the basis of product, it is classified into inhalable insulin, oral insulin, insulin patches, CGM systems, and artificial pancreas. On the basis of demographics, it is bifurcated into adult population (>14 years) and child population (≤14 years). By indication, it is divided into type 1 diabetes and type 2 diabetes. On the basis of end users, it is categorized into diagnostics/clinics, ICUs, and home healthcare. Region-wise, the market is analyzed across North America, Europe, Asia-Pacific, and LAMEA.
The key market players profiled in the report include Abbott Laboratories, Medtronic, Inc., Sanofi S.A., Novo Nordisk, MannKind Corporation, Eli Lilly and Company, Dexcom, Inc., Senseonics Holding, Inc., Glysens Incorporated, and Johnson & Johnson.
The main factors that drive the growth of the next generation diabetes therapy and the drug delivery market include, the benefits of using these advanced devices over conventional products and rise in the healthcare expenditure.
In addition, rise in incidences of diabetes globally and increase in the disposable income among the diabetic patients, further supplement the global next generation diabetes therapy and drug delivery market growth.
Conversely lack of awareness, cost restrains in the developing regions, and less variability in products are expected to obstruct the growth of the market during forecast years. On the other hand, development of affordable products with fewer side effects and presence of undiagnosed diabetic patients globally are expected to offer profitable opportunities for the growth of the market during the forecast period.
The global next generation diabetes therapy and drug delivery market is segmented based on product, demographic, indication, end user, and region. On the basis of product, it is classified into inhalable insulin, oral insulin, insulin patches, CGM systems, and artificial pancreas. On the basis of demographics, it is bifurcated into adult population (>14 years) and child population (≤14 years). By indication, it is divided into type 1 diabetes and type 2 diabetes. On the basis of end users, it is categorized into diagnostics/clinics, ICUs, and home healthcare. Region-wise, the market is analyzed across North America, Europe, Asia-Pacific, and LAMEA.
The key market players profiled in the report include Abbott Laboratories, Medtronic, Inc., Sanofi S.A., Novo Nordisk, MannKind Corporation, Eli Lilly and Company, Dexcom, Inc., Senseonics Holding, Inc., Glysens Incorporated, and Johnson & Johnson.
Key Benefits For Stakeholders
- This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the next generation diabetes therapy and drug delivery market analysis from 2020 to 2030 to identify the prevailing next generation diabetes therapy and drug delivery market opportunities.
- The market research is offered along with information related to key drivers, restraints, and opportunities.
- Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
- In-depth analysis of the next generation diabetes therapy and drug delivery market segmentation assists to determine the prevailing market opportunities.
- Major countries in each region are mapped according to their revenue contribution to the global market.
- Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
- The report includes the analysis of the regional as well as global next generation diabetes therapy and drug delivery market trends, key players, market segments, application areas, and market growth strategies.
Key Market Segments
By Product
- Inhalable Insulin
- Oral Insulin
- Insulin Patches
- CGM Systems
- Artificial Pancreas
By Demographic
- Adult Population (and14years)
- Child Population (14years)
By Indication
- Type 1 Diabetes
- Type 2 Diabetes
By End User
- Diagnostic/Clinics
- ICUs
- Home Healthcare
By Region
- North America
- U.S.
- Canada
- Mexico
- Europe
- Germany
- France
- U.K.
- Italy
- Spain
- Rest of Europe
- Asia-Pacific
- China
- Japan
- India
- Australia
- South Korea
- Rest of Asia-Pacific
- LAMEA
- Brazil
- Saudi Arabia
- South Africa
- Rest of LAMEA
Key Market Players
- Abbott laboratories
- Dexcom, Inc
- Eli Lilly and Company
- Glysens Incorporated
- Johnson & Johnson
- MannKind Corporation
- Medtronic plc
- Novo Nordisk A/S
- Sanofi S.A.
- Senseonics Holdings, Inc.
Please note:
- Online Access price format is valid for 60 days access. Printing is not enabled.
- PDF Single and Enterprise price formats enable printing.
Table of Contents
CHAPTER 1: INTRODUCTION
CHAPTER 2: EXECUTIVE SUMMARY
CHAPTER 3: MARKET OVERVIEW
CHAPTER 4: NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET, BY PRODUCT
CHAPTER 5: NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET, BY DEMOGRAPHIC
CHAPTER 6: NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET, BY INDICATION
CHAPTER 7: NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET, BY END USER
CHAPTER 8: NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET, BY REGION
CHAPTER 9: COMPANY LANDSCAPE
CHAPTER 10: COMPANY PROFILES
LIST OF TABLES
LIST OF FIGURES
Executive Summary
According to this report titled, 'Next Generation Diabetes Therapy and Drug Delivery Market,' the Next Generation Diabetes Therapy and Drug Delivery Market size was valued at $7.1 billion in 2020, and is estimated to reach $28.0 billion by 2030, growing at a CAGR of 14.28% from 2021 to 2030. Next generation diabetes therapy and drug delivery devices are used to check the blood glucose levels and deliver insulin into the body. Next generation diabetes drug delivery systems, such as oral and inhalable insulin, help introduce insulin into the patient’s body without causing pain and reduce the risk of skin irritation owing to frequent use of needles. Advancements in diabetes therapy systems, such as insulin patch, continuous glucose monitoring (CGM) system, and artificial pancreas, are frequently used to detect the glucose levels and adjust the insulin levels to manage the change in glucose levels.The major factors that impact the growth of the Next Generation Diabetes Therapy and Drug Delivery Market trends include rise in number of diabetic patients and the benefits of using advanced diabetic devices, such as artificial pancreas and insulin patches over conventional products. In addition, increase in disposable income among the diabetic patients and technological advancement of next generation diabetic products, further boost the growth of the market. Furthermore, rise in healthcare expenditure in the developing countries, such as India and China, is expected to offer profitable opportunities for the growth of the market during the forecast period. However, lack of awareness, less variability in products, and cost restrains in the developing regions are expected to hamper the market growth.
COVID-19 is a large family of viruses that causes illness ranging from common cold to more severe respiratory diseases. The Next Generation Diabetes Therapy Market also declined in 2020 due to factors such as a decline in diabetes services, reduced access to specialists, treatment interruption, delays and disruption in clinical trials and disrupted supply chain and challenges. However, the market is anticipated to witness recovery in 2021, and show stable growth for next generation diabetes therapy and drug delivery market in the coming future.
The next generation diabetes therapy and Drug Delivery Industry market is segmented based on product, demographic, indication, end user, and region. On the basis of product, it is bifurcated into inhalable insulin, oral insulin, insulin patches, CGM systems, and artificial pancreas. The CGM systems dominated the global market in 2020, and is expected to remain dominant during the forecast period, owing to advantages of these systems as compared to conventional diabetic products, such as ease of usage and efficient & early detection of change in blood glucose levels.
On the basis of demographic, the market is classified into adult population (>14 years) and child population (≤14 years). The adult population segment dominated the global market in 2020, and is anticipated to continue this trend during the forecast period. This is attributed to increase in prevalence of diabetes in adult population due to unhealthy lifestyle.
On the basis of indication, the market is segmented into type 1 diabetes and type 2 diabetes. The type 2 diabetes segment dominated the global market in 2020, and is anticipated to continue this trend during the forecast period. This is attributed to increase in cases of type-2 diabetic due to increase in urbanization, unhealthy diet, and reduced physical activity.
By end user, the market is segregated into diagnostics/clinics, ICUs, and home healthcare. The diagnostics/clinics dominated the global market in 2020, and is anticipated to continue this trend during the forecast period, owing to increase in procurement of the products from diagnostics and clinics by diabetic patients.
According to Onkar Sumant, Manager, Healthcare, 'rise in the number of diabetic patients and the benefits of using advanced diabetic devices, such as artificial pancreas and insulin patches over conventional products, are expected to boost the growth of next generation diabetes therapy and drug delivery market. Furthermore, increase in disposable income among the diabetic patients and technological advancement of next generation diabetic products are anticipated to fuel the market growth.'
Key findings of the Study
- On the basis of product, the CGM system held largest share in the global market in 2020.
- On the basis of demographic, the adult population held the largest market share in 2020 and is expected to remain dominant during the forecast period.
- On the basis of indication, the type-2 diabetes segment held the largest share in the global market in 202.
- By end user, the diagnostic/clinics segment held the largest market share in 2020 and is anticipated to continue this trend during the forecast period.
- Region-wise, North America is expected to experience growth at the highest rate, registering a CAGR of 13.23% during the forecast period.
- The North America market was dominant, in terms of revenue among other regions in 2020, owing to rise in the number of diabetic patients, high adoption rate of next generation diabetic products and emergence of more advanced products, presence of major key players, and development in technology for healthcare in the region.
- On the other hand, Next Generation Diabetes Therapy and Drug Delivery Market growth in the Asia-Pacific region was the third-largest contributor in the market in 2020, and is expected to register the fastest CAGR during the forecast period, owing to rise in R&D for the advancement of diabetic products in the countries of Asia-Pacific, growth in healthcare expenditures, and increase in awareness about the benefits of using next generation diabetic products, such as better management of blood glucose level.
Companies Mentioned
- Abbott laboratories
- Dexcom, Inc
- Eli Lilly and Company
- Glysens Incorporated
- Johnson & Johnson
- MannKind Corporation
- Medtronic plc
- Novo Nordisk A/S
- Sanofi S.A.
- Senseonics Holdings, Inc.
Methodology
The analyst offers exhaustive research and analysis based on a wide variety of factual inputs, which largely include interviews with industry participants, reliable statistics, and regional intelligence. The in-house industry experts play an instrumental role in designing analytic tools and models, tailored to the requirements of a particular industry segment. The primary research efforts include reaching out participants through mail, tele-conversations, referrals, professional networks, and face-to-face interactions.
They are also in professional corporate relations with various companies that allow them greater flexibility for reaching out to industry participants and commentators for interviews and discussions.
They also refer to a broad array of industry sources for their secondary research, which typically include; however, not limited to:
- Company SEC filings, annual reports, company websites, broker & financial reports, and investor presentations for competitive scenario and shape of the industry
- Scientific and technical writings for product information and related preemptions
- Regional government and statistical databases for macro analysis
- Authentic news articles and other related releases for market evaluation
- Internal and external proprietary databases, key market indicators, and relevant press releases for market estimates and forecast
Furthermore, the accuracy of the data will be analyzed and validated by conducting additional primaries with various industry experts and KOLs. They also provide robust post-sales support to clients.
LOADING...
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 254 |
| Published | March 2022 |
| Forecast Period | 2020 - 2030 |
| Estimated Market Value ( USD | $ 7080.6 million |
| Forecasted Market Value ( USD | $ 28044.23 million |
| Compound Annual Growth Rate | 14.8% |
| Regions Covered | Global |
| No. of Companies Mentioned | 10 |
